Effects of application of electronic-patient reported outcome system on QOL and compliance in breast cancer patients receiving adjuvant hormonal therapy: a randomized controlled trial.
Not Applicable
- Conditions
- Breast cancer
- Registration Number
- JPRN-UMIN000044502
- Lead Sponsor
- Showa University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- Female
- Target Recruitment
- 130
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who had received hormonal therapy in the past. Patients with recurrent breast cancer. Patients who cannot evaluate symptoms due to mental illness or cognitive dysfunction. Patients who cannot operate smartphones or tablets. Patients who cannot use of email.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the impact of electronic-PHR/PRO systems on QOL in breast cancer patients on hormonal therapy?
How does electronic-PHR/PRO compare to traditional methods in improving adherence to adjuvant hormonal therapy for breast cancer?
Are there specific biomarkers associated with enhanced QOL outcomes in breast cancer patients using electronic-PHR/PRO during hormonal therapy?
What adverse events are commonly reported in breast cancer patients using electronic-PHR/PRO systems for adjuvant hormonal therapy management?
What combination therapies or digital health interventions are being explored alongside hormonal therapy for breast cancer patient adherence and QOL improvement?